Why the study?
Women face higher post-MI mortality and heart failure risk despite smaller infarcts, creating a need to evaluate antifibrotic therapies such as nebivolol-valsartan compared with sacubitril-valsartan.
Does sacubitril-valsartan or nebivolol-valsartan improve left ventricular remodeling and reduce fibrosis in female rats following chronic myocardial infarction?
Does sacubitril-valsartan or nebivolol-valsartan improve left ventricular remodeling and reduce fibrosis in female rats following chronic myocardial infarction?
Answers are grounded in this paper and cite their sources.
In a female rat model of myocardial infarction, sacubitril-valsartan safely attenuated cardiac fibrosis and remodeling, whereas early administration of nebivolol-valsartan increased mortality.
La fibrosis cardiaca tras un infarto de miocardio (IM) provoca una remodelación ventricular izquierda adversa e insuficiencia cardiaca, observándose patrones distintos en las mujeres.A pesar de presentar infartos de menor tamaño y una menor actividad profibrótica, las mujeres tienen un mayor riesgo de mortalidad tras un IM y de insuficiencia cardiaca.Dado que las terapias actuales se dirigen directamente a la fibrosis, el estudio de estos mecanismos es esencial para desarrollar y evaluar tratamientos, incluidos los fármacos aprobados para la insuficiencia cardiaca, como el sacubitril-valsartán. El objetivo de este estudio fue comparar y evaluar la combinación de nebivolol-valsartán (NV) frente a sacubitril-valsartán (SV) como tratamiento conocido para el infarto crónico en ratas hembras.Se utilizaron ratas Wistar de 26 semanas de edad.Los animales se dividieron en cuatro grupos (n = 6): 1) control (SHAM); 2) infarto de miocardio (LADL); 3) LADL + sacubitril 30 mg/kg/día + valsartán 28 mg/kg/día (LADL + SV); 4) LADL + valsartán 30 mg/kg/día + nebivolol 5 mg/kg/día (LADL + NV).La inducción del infarto se realizó mediante ligadura permanente de la arteria coronaria descendente anterior izquierda.Los grupos tratados recibieron sus tratamientos inmediatamente después de la inducción del infarto durante dos semanas.Las ratas fueron sacrificadas mediante dislocación cervical y se extrajeron los corazones y los pulmones de todos los grupos para su análisis histológico mediante tinción de Van Gieson y HE.La combinación de ABSTRACT Cardiac fibrosis following a myocardial infarction (MI) leads to adverse left ventricular remodeling and heart failure, with distinct patterns observed in women.Despite having smaller infarcts and less profibrotic activity, women have a higher risk of post-MI mortality and heart failure.Since on therapies currently target fibrosis directly, studying these mechanisms is essential for developing and testing treatments, including approved heart failure drugs such as sacubitril-valsartan.This study aimed to compare and evaluate the combination of nebivolol-valsartan (NV) vs sacubitril-valsartan (SV) as a known treatment for chronic infarction in female rats; 26-weeks-old Wistar rats were used.The animals were divided into four groups (n = 6): 1) control (SHAM); 2) myocardial infarction (LADL); 3) LADL + sacubitril 30 mg/kg/day + valsartan 28 mg/kg/day (LADL + SV); 4) LADL + valsartan 30 mg/kg/day + nebivolol 5 mg/kg/day (LADL + NV).Infarct induction was performed by permanent ligation of the left anterior descending coronary artery.The treated groups received their treatments right after infarct induction for two weeks.The rats were euthanized by cervical dislocation and hearts and lungs were obtained from all groups for histology using Van Gieson and HE staining.The NV combination resulted in 50% mortality in animals, promoting pulmonary congestion and pleural effusion.Therefore, the administration of the NV combination at different times was proposed, after three and seven days post-infarction.
No takes yet. Share an insight, caveat, or question.
Pérez-García et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: